

# **ANNEX A**

# **RESULTS**

## **CANCER HEALTH INDICATORS DESCRIBED IN THE FORMS BY EUROCHIP**

**EUROCHIP - European Cancer Health Indicator Project  
FINAL REPORT**

**Project leader:**

Dr. Andrea Micheli  
Unit of Epidemiology  
Istituto Nazionale per lo Studio e la Cura e dei Tumori  
Via Venezian, 1  
20133 Milan  
Italy

**European Commission**

Directorate for Public Health and Safety at Work  
DG SANCO/G3  
GRANT AGREEMENT  
n°SI2.328473 (2001CVG3-515)

# INDEX

<b>INTRODUCTION</b>	1
---------------------	---

## INDICATORS ON PREVENTION

<i>Code</i>	<i>Name of indicator</i>	
ANNEX 1	Indicators from other HMP projects	2
ANNEX 2	Health European survey	3
A.1Pr.01	Consumption of fruit and vegetables	4 (DF)
A.1Pr.02	Consumption of alcohol	5 (DF)
A.1Pr.03	Body Mass Index distribution in the population	6 (DF)
A.1Pr.04	Physical activity	7 (DF)
ANNEX 3	Summary from the WHO Report "Tobacco Country profiles"	8
A.1Pr.05a	Prevalence of current tobacco smokers among adults	9 (DF+MF)
A.1Pr.05b	Prevalence of tobacco smokers among 10-14	11 (DF+MF)
A.1Pr.05c	Prevalence of ex-smokers	13 (DF+MF)
A.1Pr.05d	Prevalence of exposure to Environmental Tobacco Smoke (ETS)	15 (DF+MF)
A.1Pr.06	Exposure to sun radiation	17 (DF+MF)
A.1Pr.07	PM10 (particulate matter $\leq 10\mu 3$ ) emissions	19 (DF)
A.1Pr.08	Indoor radon exposure	20 (DF+MF)
A.1Pr.09	Prevalence of occupational exposure to carcinogens	22 (DF+MF)
A.1Pr.10a/b	Exposure to asbestos: mesothelioma incidence and mortality trends	24 (DFs+MF)
A.1Pr.11	Prevalence of use of Hormonal Replacement Treatment drugs	27 (DF)

## INDICATORS ON EPIDEMIOLOGY AND CANCER REGISTRATION

<i>Code</i>	<i>Name of indicator</i>	
A.2Ep.1	Population covered by Cancer Registries	28 (DF+MF)
A.2Ep.2	Cancer incidence rates, trends and projections	30 (DF)
A.2Ep.3	Cancer relative survival rates, trends and projections	31 (DF)
A.2Ep.4	Cancer prevalence proportions, trends and projections	32 (DF)
A.2Ep.5a	Cancer mortality rates, trends and projections	33 (DF)
A.2Ep.5b	Person-years of life lost due to cancer	34 (DF+MF)
A.2Ep.6a	Stage at diagnosis: percentage of cases with early diagnosis	36 (DF+MF)
A.2Ep.6b	Stage at diagnosis: percent of cases with a metastatic test	38 (DFs+MF)

## INDICATORS ON SCREENINGS

<i>Code</i>	<i>Name of indicator</i>	
A.3Sc.1	Percentage of women that have undergone a mammography	43 (DF+MF)
A.3Sc.2	Percentage of women that have undergone a cervical cytology examination	45 (DF+MF)
A.3Sc.3	Percentage of persons that have undergone a colo-rectal cancer screening test	47 (DF+MF)
ANNEX 4	National evaluation in HMP of the organized screening process indicators	49 (DF+MF)
A.3Sc.4a	Organised screening coverage	50 (DF+MF)
A.3Sc.4b	Screening recall rate	52 (DF+MF)
A.3Sc.4c	Screening detection rate	54 (DF+MF)
A.3Sc.4d	Screening localised cancers	56 (DF+MF)
A.3Sc.4e	Screening positive predictive value	58 (DF+MF)
A.3Sc.4f	Screening benign/malignant biopsy ratio	60 (DF+MF)
A.3Sc.4g	Screening interval cancers	62 (DF+MF)
A.3Sc.4h	Screening specificity	64 (DF+MF)

**DF:** DESCRIPTIVE FORM

**MF:** METHODOLOGICAL FORM

**DFs:** DESCRIPTIVE FORMS FOR DIFFERENT CANCER SITES

## INDICATORS ON TREATMENT AND CLINICAL ASPECTS

<i>Code</i>	<i>Name of indicator</i>	
ANNEX 5	Specification of the various phases of the disease history	66
A.4Tr.1	Delay of cancer treatment	67 (MF+DF)
A.4Tr.2	Percentage of radio-therapy systems on population	69 (DF+MF)
A.4Tr.3	Percentage of diagnostic Computed Axial Tomographies (CTs) on population	71 (DF+MF)
A.4Tr.4	Percentage of Positron Emission Tomographies (PETs) on population	73 (DF+MF)
A.4Tr.5	Percentage of magnetic resonance systems on population	75 (DF+MF)
A.4Tr.6	Compliance with best oncology practice	77 (MF+DFs)
ANNEX 6	Various specifications from "Compliance with best oncology practice"	78
A.4Tr.7	Use of morphine for cancer patients	88 (DF)
A.4Tr.8	Proportion of patients treated with palliative radiotherapy	89 (DF)

## INDICATORS ON SOCIAL AND MACRO-ECONOMIC VARIABLES

<i>Code</i>	<i>Name of indicator</i>	
A.5Mv.01	Educational level attained	90 (DF)
A.5Mv.02	Total income by decile	91 (DF)
A.5Mv.03	Gini's index	92 (DF)
A.5Mv.04	Gross Domestic Product	93 (DF)
A.5Mv.05	Total Social Expenditure	94 (DF)
A.5Mv.06	Total National Expenditure on Health	95 (DF)
A.5Mv.07	Total Public Expenditure on Health	96 (DF)
A.5Mv.08	Anti-tobacco regulations	97 (DF+MF)
A.5Mv.09a	Public expenditure for cancer prevention on anti-tobacco activity	99 (DF+MF)
A.5Mv.09b	Public expenditure for population-based Cancer Registries	101 (DF+MF)
A.5Mv.09c	Public expenditure for organized mass screening programmes for cancer	103 (DF+MF)
A.5Mv.09d	Public Expenditure on cancer drugs	105 (DF)
A.5Mv.09e	Public Expenditure for cancer research	106 (DF+MF)
A.5Mv.09f	Estimated cost for cancer patients	108 (DF)
A.5Mv.10	Age distribution in 2010, 2020, 2030	109 (DF)
A.5Mv.11	Life-table quantities	110 (DF)

**DF:** DESCRIPTIVE FORM

**MF:** METHODOLOGICAL FORM

**DFs:** DESCRIPTIVE FORMS FOR DIFFERENT CANCER SITES

The index above also coincides with the list of the indicators.

## INTRODUCTION

This annex presents the indicators proposed by EUROCHIP and their description.

The list of indicators was grouped along three axes: (a) natural history of disease, (b) type of factor (demographic, socio-economic, health status, determinant of health, or health system related) and (c) cancer site.

At the end of various discussions and meetings a final list was proposed by the Panel of Experts concluding the work with 52 indicators (26 at high priority, 15 of which proposed directly by EUROCHIP).

These 52 indicators are classified by domain as follows:

(in brackets are the number of indicators proposed by EUROCHIP alone)

- a. **PREVENTION: 11 (4)**
  - Lifestyle: 5 (0)
  - Environment & Occupational risk: 5 (4)
  - Medicaments: 1 (0)
- b. **EPIDEMIOLOGY AND CANCER REGISTRATION: 6 (2)**
  - Cancer registration coverage: 1 (1)
  - Epidemiological measure: 5 (1)
- c. **SCREENING: 11 (11)**
  - Screening coverage: 3 (3)
  - National evaluation of organised screening process indicators: 8 (8)
- d. **TREATMENT AND CLINICAL ASPECTS: 8 (8)**
  - Health system delay: 1 (1)
  - Resources: 4 (4)
  - Treatment: 1 (1)
  - Palliative care: 2 (2)
- e. **SOCIAL AND MACRO-ECONOMIC VARIABLES: 16 (6)**
  - Social indicators: 3 (0)
  - Macro economic indicators: 11 (6)
  - Demographic indicators: 2 (0)

The [Annex A](#) is organized as follows:

- an introduction with the list of the indicators as an index (this file);
- each indicator is described by a “descriptive form” showing definition, rationale, use, methodological characteristics, etc. (See file “**ANNEX A2 – Descriptive forms.mdb**” in ACCESS 97)
- the indicators proposed by EUROCHIP alone are also described by a “methodological form” with indications of context, sources, standardization and validity (See file “**ANNEX A3 – Methodological forms.doc**”)
- each annex describes the indicators, summarising from other projects or articles or parts of articles validity (in the file “**ANNEX A3 – Methodological forms.doc**”)

This report was produced by a contractor for Health & Consumer Protection Directorate General and represents the views of the contractor or author. These views have not been adopted or in any way approved by the Commission and do not necessarily represent the view of the Commission or the Directorate General for Health and Consumer Protection. The European Commission does not guarantee the accuracy of the data included in this study, nor does it accept responsibility for any use made thereof.